$2.88
−0.69%Oct 13, 2026, 11:00 UTC
NovaBridge Biosciences granted NovaBridge Biosciences exclusive rights to develop and commercialize HT006.2.2 worldwide except in Greater China.
Source:Aug 20, 2026, 11:00 UTC
NovaBridge Biosciences reported financial results for the six months ended June 30, 2026, and provided a business update on pipeline momentum and strategic execution.